Vanda制药公司的CFO在收入微薄的情况下出售股票,因为林业发展局对Hetlioz的核准希望提高投资者的利益。 Vanda Pharmaceuticals' CFO sold shares amid weak earnings, as FDA approval hopes for Hetlioz lifted investor interest.

Vanda制药公司(VNDA)CFO Kevin Patrick Moran于2026年3月2日出售42 442股,每股8.27美元,股份减少9.35%,达411 380股。 Vanda Pharmaceuticals (VNDA) CFO Kevin Patrick Moran sold 42,442 shares on March 2, 2026, at $8.27 each, reducing his stake by 9.35% to 411,380 shares. 出售在证交会档案中披露,是在财务结果不佳的情况下进行的:Q4收入每股0.21美元,收入低于估计数,股票关闭8.10美元。 The sale, disclosed in an SEC filing, occurred amid weak financial results: Q4 earnings missed by $0.21 per share, revenue fell short of estimates, and the stock closed at $8.10. 该公司侧重于CNS病症和罕见疾病,为Hetlioz举行了具有里程碑意义的林业发展局听证会,这有可能增加批准机会。 The company, focused on CNS disorders and rare diseases, secured a landmark FDA hearing for Hetlioz, potentially improving approval chances. 机构投资者持有88.14%的股份,分析师维持“机动购买”共识,目标为14.90加元。 Institutional investors hold 88.14% of shares, and analysts maintain a "Moderate Buy" consensus with a $14.90 target.